Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc. and Eli ...

Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc.